Bisantrene
Allogeneic Stem Cell Transplantation
Sheba Medical CenterSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Allogeneic Stem Cell Transplantation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ruxolitinib Massachusetts General Hospital | Phase 2 | CCC |
Cartemis-1 Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Phase 1/2 | CCC |
Interferon Gamma-1B Sawa Ito, MD | Early Phase 1 | CC |
Siremadlin Novartis Pharmaceuticals | Phase 1/2 | CC |
Same molecule, other indications
Bisantrene is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →